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Short Communication
A new marker for testicular cancer
S. Metcalfe' & K. Sikora
'Department ofSurgery, Addenbrooke's Hospital, 2Ludwig Institutefor Cancer Research, MRC Centre, Hills
Road, Cambridge, UK.
The recent dramatic success in the treatment of
testicular cancer is due to advances in patient
management involving computerised tomography,
effective combination chemotherapy, and accurate
measurement of the biochemical markers a-
foetoprotein (a-FP) and ,B subunit of human
gonadotrophin (#HCG) (Ellis & Sikora, 1984).
These two proteins are abnormally high in the
serum of most teratoma patients where they
provide a reliable index of disease presence.
However, some 30% of teratoma patients do not
exhibit a raised aFP or PHCG at diagnosis and
here these markers cannot be used to monitor
disease status (Coppack et al., 1983). In seminoma,
no reliable biochemical marker is known (although
placental alkaline phosphate is currently being
investigated). We have studied patients with
testicular tumours and compared standard markers
with a new haemagglutination test for tumour
presence.
B5 is a rat monoclonal antibody (IgG) which has
been found to agglutinate erythrocytes from
patients with malignant disease (Metcalfe et al.,
1984). The incidence of B5 positivity is 80% in
cancer patients which, when compared to a normal
incidence of 20% in control groups, implies that
people who are normally B5 negative become B5
positive if they develop cancer. B5 haemag-
glutination was tested in 79 patients attending the
testicular tumour clinic over a period of 16 months
using methods reported previously (Metcalfe et al.,
1984). The overall results are given in Table I. We
found that (a) both teratoma and seminoma
patients are B5 positive; (b) individual patients
revert to a B5 negative state when the tumour is
successfully removed; (c) some patients remain B5
positive, although clinically without active disease:
in most cases we anticipate that this group
represents those individuals who are normally B5
positive, although the possibility of persistent
disease should be considered, as was found in two
patients in this study; and (d) the timing of the
change in the B5 status after tumour removal
relates - as expected - to the erythrocyte life span.
It is interesting to consider in more detail those
patients who were monitored over a prolonged
period of up to two years in this study. In Figure
la it can be seen that three seminoma patients,
negative for aFP and flHCG were B5 positive and
subsequently recovered a B5 negative status at
similar rates, plateauing about one year after
removal of the primary tumour. A similar time
course was followed by two of the three teratoma
patients represented in Figure lb: one of these had
very high ,BHCG and aFP levels at diagnosis, and
also showed a strong positivity with B5; another
patient was first monitored with B5 three months
after a second course of chemotherapy for recurrent
tumour.Thisrecurrencewasassociatedwithabnormal
levels of flHCG and aFP, and with B5 positivity.
The third patient in Figure lb switched to B5
negative within 6 months; at presentation this
patient was asymptomatic, was negative for PiHCG
and aFP, and had a very small tumour removed.
Thus, for this patient, B5 was clearly a sensitive
indicator of tumour presence. In Figure Ic two
further patients with a more complex case history
of teratoma are shown, both of whom showed a
rapid recovery of normal ,BHCG and aFP levels
after surgery. One had had invasive disease with
lung metastases and showed a prolonged B5
positive status followed by an irregular change
towards a negative status as the disease responded
to treatment and regressed. The second patient
showed no shift towards a B5 negative state,
although clinically assessed as being free from
disease. After a year this patient was considered to
be a "false positive" B5. However, at 17 months
the patient was discovered to have residual disease,
although his aFP and fHCG levels remained
normal.
This study indicates a role for B5 in the clinical
management of testicular cancer, and especially for
seminoma patients. Bimonthly monitoring with B5
gives information on tumour status for many of
those patients who are oeFP and PHCG negative at
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Figure 1 Comparison of B5, aFP and ,BHCG markers in 8 patients with testicular tumour monitored for up
to 24 months. Individual patient details are given in the text. The time scale in all graphs is as that
represented in l(c). In 1(b), patient (0) had had a very small tumour; patient (X) was recovering from relapse,
and had received chemotherapy starting at time "zero". For all other patients, time "zero" represents the time
when the primary tumour was surgically removed. The time of clinical identification of recurrent tumour in
patient 1(c) (0) is indicated by an arrow.
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Table I Comparison between B5, aFP and PHCG markers in testicular
cancer.
At Complete Persistent Recurrent
diagnosis remission disease disease
Teratoma
No. patients 18 32 3 4
B5 +ev 17a 7 3 4
aFP +ve 12 0 2 3
PHCG +ve 14 0 1 4
Seminoma
No. patients 10 10 2
B5 +ve 10 1 2
aFP +ve 0 0 0
,BHCG +ve 4 0 0
aOne patient in this study was B5 negative when tested soon after
surgery: his fiHCG and aFP markers had been markedly raised. This patient
had required blood transfusions, a factor which might explain this initial
B5 negative result, since the patient became B5 positive at 3 months, before
reverting to a B5 negative status at 7 months. Initial observations on 13 of
these patients have been reported elsewhere (Metcalfe et al., 1984).
diagnosis and B5 appears to be a sensitive indicator
of residual tumour/recurrence.
In conclusion, we feel that the simple B5 test is a
worthwhile addition to the monitoring protocol for
testicular tumour patients, especially where aFP
and ,BHCG levels remain normal. In addition,
current trials of surveillance alone in early stage
seminoma would benefit considerably from an
efficient marker such as B5.
This work was aided by grants from the Medical Research
Council and the Cancer Research Campaign.
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